150 related articles for article (PubMed ID: 16283274)
1. Identification of CYP2D6 impaired functional alleles in Mexican Americans.
Luo HR; Gaedigk A; Aloumanis V; Wan YJ
Eur J Clin Pharmacol; 2005 Dec; 61(11):797-802. PubMed ID: 16283274
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos.
Sosa-Macías M; Dorado P; Alanis-Bañuelos RE; Llerena A; Lares-Asseff I
Pharmacology; 2010; 86(1):30-6. PubMed ID: 20588073
[TBL] [Abstract][Full Text] [Related]
3. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.
Casner PR
J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 polymorphism in a Mexican American population.
Mendoza R; Wan YJ; Poland RE; Smith M; Zheng Y; Berman N; Lin KM
Clin Pharmacol Ther; 2001 Dec; 70(6):552-60. PubMed ID: 11753272
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.
López M; Guerrero J; Jung-Cook H; Alonso ME
Eur J Clin Pharmacol; 2005 Nov; 61(10):749-54. PubMed ID: 16249913
[TBL] [Abstract][Full Text] [Related]
6. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
[TBL] [Abstract][Full Text] [Related]
7. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population.
Kiyotani K; Shimizu M; Kumai T; Kamataki T; Kobayashi S; Yamazaki H
Eur J Clin Pharmacol; 2010 Oct; 66(10):1065-8. PubMed ID: 20700584
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.
Gaedigk A; Bradford LD; Alander SW; Leeder JS
Drug Metab Dispos; 2006 Apr; 34(4):563-9. PubMed ID: 16415111
[TBL] [Abstract][Full Text] [Related]
9. [Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese].
Cai W; Chen B; Tao X; Ling S; Zhang Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Jun; 17(3):181-4. PubMed ID: 10837520
[TBL] [Abstract][Full Text] [Related]
10. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.
Kubota T; Yamaura Y; Ohkawa N; Hara H; Chiba K
Br J Clin Pharmacol; 2000 Jul; 50(1):31-4. PubMed ID: 10886115
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.
Panserat S; Sica L; Gérard N; Mathieu H; Jacqz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1999 Jan; 47(1):121-4. PubMed ID: 10073750
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
13. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 genotype and phenotype relationship in South Indians.
Naveen AT; Prasanna T; Farzana BL; Rajan S; Adithan C
J Postgrad Med; 2006; 52(4):253-6. PubMed ID: 17102541
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population.
Tateishi T; Chida M; Ariyoshi N; Mizorogi Y; Kamataki T; Kobayashi S
Clin Pharmacol Ther; 1999 May; 65(5):570-5. PubMed ID: 10340923
[TBL] [Abstract][Full Text] [Related]
16. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
Raimundo S; Toscano C; Klein K; Fischer J; Griese EU; Eichelbaum M; Schwab M; Zanger UM
Clin Pharmacol Ther; 2004 Aug; 76(2):128-38. PubMed ID: 15289790
[TBL] [Abstract][Full Text] [Related]
17. The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution.
Ikenaga Y; Fukuda T; Fukuda K; Nishida Y; Naohara M; Maune H; Azuma J
Drug Metab Pharmacokinet; 2005 Apr; 20(2):113-6. PubMed ID: 15855722
[TBL] [Abstract][Full Text] [Related]
18. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
[TBL] [Abstract][Full Text] [Related]
19. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.
Gaedigk A; Gotschall RR; Forbes NS; Simon SD; Kearns GL; Leeder JS
Pharmacogenetics; 1999 Dec; 9(6):669-82. PubMed ID: 10634130
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.
Gaedigk A; Bhathena A; Ndjountché L; Pearce RE; Abdel-Rahman SM; Alander SW; Bradford LD; Rogan PK; Leeder JS
Pharmacogenomics J; 2005; 5(3):173-82. PubMed ID: 15768052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
